Recipharm AB sells majority stake in Nitin Lifesciences Limited to Synokem Pharmaceuticals Limited

EY provided financial advisory services to Recipharm AB on the divestment of majority stake in Nitin Lifesciences Limited to TA Associates-owned Synokem Pharmaceuticals Limited.

Headquartered in Sweden, Recipharm AB is amongst the top 5 global Contract Development and Manufacturing Organisations (CDMO) players providing end-to-end development and manufacturing services to leading pharmaceutical and biotech companies.

Founded in 1994, Nitin Lifesciences Limited, is an established CDMO of injectable products with a focus on liquid ampoules, liquid vials, dry powder, eye and ear drops, and lyophilized vials.

Synokem Pharmaceuticals Limited, majority owned by TA Associates, is one of India’s leading CDMOs. It has three state-of the art manufacturing units, manufacturing various oral solid and liquid dosage forms at Haridwar.

This partnership with TA Associates-owned Synokem Pharmaceuticals will help strengthen the combined potential of Nitin Lifesciences and Synokem in the Indian CDMO landscape.